{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:00:45Z","timestamp":1793660445771,"version":"4.5.1"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"},{"start":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T00:00:00Z","timestamp":1634688000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1R01 CA102713"],"award-info":[{"award-number":["1R01 CA102713"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA033572"],"award-info":[{"award-number":["P30CA033572"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA229510-01"],"award-info":[{"award-number":["R01CA229510-01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1R01 CA102713"],"award-info":[{"award-number":["1R01 CA102713"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA033572"],"award-info":[{"award-number":["P30CA033572"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA229510\u201001"],"award-info":[{"award-number":["R01CA229510\u201001"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,1,1]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>Background<\/jats:p>\n               <jats:p>Mogamulizumab is a humanized antibody against chemokine receptor type 4. It was recently approved by the US Food and Drug Administration for relapsed or refractory mycosis fungoides (MF) and S\u00e9zary syndrome (SS). The most commonly reported adverse event in the phase III licensing trial was drug eruption (28%), now termed mogamulizumab-associated rash (MAR). Clinical recommendations about MAR and its treatment differ between the current package insert and postapproval insights reported from two single-centre studies that focused on its characterization, but less so on outcomes and clinicopathological differentiation from cutaneous T-cell lymphoma (CTCL).<\/jats:p>\n               <jats:p>Objectives<\/jats:p>\n               <jats:p>To describe our experience in the diagnosis of MAR and treatment of patients with CTCL with mogamulizumab.<\/jats:p>\n               <jats:p>Methods<\/jats:p>\n               <jats:p>This is a single-centre retrospective case series study.<\/jats:p>\n               <jats:p>Results<\/jats:p>\n               <jats:p>We found a higher incidence of MAR in patients with CTCL (17 of 24, 68%) than previously reported. MAR development is associated with complete (11 of 17) or partial (four of 17) responses, with an overall response rate of 88%, compared with 29% (two of seven) in patients without MAR. Diagnosis of MAR may be obscured by its ability to mimic key CTCL features both clinically and histologically, but an absence of T-cell-receptor clonality and relatively decreased CD4 : CD8 ratio compared with baseline lesions strongly favour MAR over recurrent disease.<\/jats:p>\n               <jats:p>Conclusions<\/jats:p>\n               <jats:p>MAR has the potential to create a significant management problem for patients on mogamulizumab. Misidentification of MAR as recurrent CTCL may detrimentally result in the premature discontinuation of mogamulizumab in patients whose disease is historically hard to treat. Thorough clinicopathological investigation of new lesions during treatment with mogamulizumab is required to inform ideal treatment decisions and achieve better outcomes.<\/jats:p>","DOI":"10.1111\/bjd.20708","type":"journal-article","created":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T15:46:28Z","timestamp":1629819988000},"page":"153-166","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Mogamulizumab efficacy is underscored by its associated rash that mimics cutaneous T-cell lymphoma: a retrospective single-centre case series"],"prefix":"10.1093","volume":"186","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3256-4340","authenticated-orcid":false,"given":"N.A.","family":"Trum","sequence":"first","affiliation":[{"name":"Division of Dermatology City of Hope Comprehensive Cancer Care Center 1500 E Duarte Rd Duarte CA 91010 USA"},{"name":"Sackler Faculty of Medicine Tel Aviv University Ramat Aviv 69978 Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Zain","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation City of Hope Comprehensive Cancer Care Center 1500 E Duarte Rd Duarte CA 91010 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9849-9887","authenticated-orcid":false,"given":"X.U.","family":"Martinez","sequence":"additional","affiliation":[{"name":"Division of Dermatology City of Hope Comprehensive Cancer Care Center 1500 E Duarte Rd Duarte CA 91010 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Parekh","sequence":"additional","affiliation":[{"name":"Department of Pathology City of Hope Comprehensive Cancer Care Center 1500 E Duarte Rd Duarte CA 91010 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Afkhami","sequence":"additional","affiliation":[{"name":"Department of Pathology City of Hope Comprehensive Cancer Care Center 1500 E Duarte Rd Duarte CA 91010 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Abdulla","sequence":"additional","affiliation":[{"name":"Division of Dermatology City of Hope Comprehensive Cancer Care Center 1500 E Duarte Rd Duarte CA 91010 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.R.","family":"Carson","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology, and Stem Cell Transplant Rush University 600 S. Paulina St Chicago IL 60612 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.T.","family":"Rosen","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematopoietic Cell Transplantation City of Hope Comprehensive Cancer Care Center 1500 E Duarte Rd Duarte CA 91010 USA"},{"name":"Beckman Research Institute City of Hope Comprehensive Cancer Care Center 1500 E Duarte Rd Duarte CA 91010 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.L.","family":"Bennett","sequence":"additional","affiliation":[{"name":"Beckman Research Institute City of Hope Comprehensive Cancer Care Center 1500 E Duarte Rd Duarte CA 91010 USA"},{"name":"Department of Comparative Medicine and Evidence Based Medicine City of Hope Comprehensive Cancer Care Center 1500 E Duarte Rd Duarte CA 91010 USA"},{"name":"College of Pharmacy University of South Carolina Columbia SC USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9698-5809","authenticated-orcid":false,"given":"C.","family":"Querfeld","sequence":"additional","affiliation":[{"name":"Division of Dermatology City of Hope Comprehensive Cancer Care Center 1500 E Duarte Rd Duarte CA 91010 USA"},{"name":"Department of Pathology City of Hope Comprehensive Cancer Care Center 1500 E Duarte Rd Duarte CA 91010 USA"},{"name":"Beckman Research Institute City of Hope Comprehensive Cancer Care Center 1500 E Duarte Rd Duarte CA 91010 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,1,1]]},"reference":[{"key":"2023010800163646600_bjd20708-bib-0001","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jamadermatol.2013.5526","article-title":"Changing incidence trends of cutaneous T-cell lymphoma","volume":"149","author":"Korgavkar","year":"2013","journal-title":"JAMA Dermatol"},{"key":"2023010800163646600_bjd20708-bib-0002","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.3390\/cancers12102921","article-title":"Epidemiology of cutaneous T-cell lymphomas: a systematic review and meta-analysis of 16,953 patients","volume":"12","author":"Dobos","year":"2020","journal-title":"Cancers"},{"key":"2023010800163646600_bjd20708-bib-0003","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1182\/blood-2015-12-611830","article-title":"How I treat mycosis fungoides and S\u00e9zary syndrome","volume":"127","author":"Whittaker","year":"2016","journal-title":"Blood"},{"key":"2023010800163646600_bjd20708-bib-0004","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11912-018-0678-x","article-title":"Systemic treatment options for advanced-stage mycosis fungoides and S\u00e9zary syndrome","volume":"20","author":"Photiou","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"2023010800163646600_bjd20708-bib-0005","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2147\/OTT.S165615","article-title":"Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma","volume":"12","author":"Ollila","year":"2019","journal-title":"Onco Targets Ther"},{"key":"2023010800163646600_bjd20708-bib-0006","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S1470-2045(18)30379-6","article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomized, controlled phase 3 trial","volume":"19","author":"Kim","year":"2018","journal-title":"Lancet Oncol"},{"key":"2023010800163646600_bjd20708-bib-0007","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J Clin Oncol"},{"key":"2023010800163646600_bjd20708-bib-0008","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-09-2697","article-title":"Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia\/lymphoma","volume":"16","author":"Ishii","year":"2010","journal-title":"Cancer Clin Res"},{"key":"2023010800163646600_bjd20708-bib-0009","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1158\/1078-0432.CCR-15-0357","article-title":"Phase Ia study of FoxP3+ CD4 Treg depletion by infusion of a humanized anti-CCR4 antibody, KW-0761, in cancer patients","volume":"21","author":"Kurose","year":"2015","journal-title":"Cancer Clin Res"},{"key":"2023010800163646600_bjd20708-bib-0010","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","article-title":"Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-CC chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"32","author":"Ogura","year":"2014","journal-title":"J Clin Oncol"},{"key":"2023010800163646600_bjd20708-bib-0011","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/bjh.13338","article-title":"Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study","volume":"169","author":"Ishida","year":"2015","journal-title":"Br J Haematol"},{"key":"2023010800163646600_bjd20708-bib-0012","doi-asserted-by":"crossref","first-page":"7275","DOI":"10.1158\/1078-0432.CCR-19-2030","article-title":"FDA approval summary: mogamulizumab-kpkc for mycosis fungoides and S\u00e9zary syndrome","volume":"25","author":"Kasamon","year":"2019","journal-title":"Cancer Clin Res"},{"key":"2023010800163646600_bjd20708-bib-0013","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/intimm\/dxu079","article-title":"CCR4 and its ligands: from bench to bedside","volume":"27","author":"Yoshie","year":"2015","journal-title":"Int Immunol"},{"key":"2023010800163646600_bjd20708-bib-0014","doi-asserted-by":"crossref","first-page":"17945","DOI":"10.1073\/pnas.1316796110","article-title":"Anti-CCR4 mAb selectively depletes effector-type FoxP3+ CD4+ regulatory T cells, evoking antitumor immune responses in humans","volume":"110","author":"Sugiyama","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023010800163646600_bjd20708-bib-0015","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/imm.13158","article-title":"Depletion of Foxp3+ regulatory T cells is accompanied by an increase in the relative abundance of Firmicutes in the murine gut microbiome","volume":"159","author":"Kehrmann","year":"2020","journal-title":"Immunology"},{"key":"2023010800163646600_bjd20708-bib-0016","first-page":"377","article-title":"CD8+ T-cell-mediated interface dermatitis after CCR4+ T-cell depletion by mogamulizumab treatment of adult T-cell leukaemia\/lymphoma","volume":"97","author":"Ito","year":"2017","journal-title":"Acta Dermatovenereol"},{"key":"2023010800163646600_bjd20708-bib-0017","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/1346-8138.12419","article-title":"Effect of anti-CCR4 monoclonal antibody (mogamulizumab) on adult T-cell leukemia-lymphoma: cutaneous adverse reactions may predict the prognosis","volume":"41","author":"Yonekura","year":"2014","journal-title":"J Dermatol"},{"key":"2023010800163646600_bjd20708-bib-0018","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1097\/PAS.0000000000001587","article-title":"Histopathologic characterization of mogamulizumab-associated rash","volume":"44","author":"Wang","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"2023010800163646600_bjd20708-bib-0019","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/jamadermatol.2019.0369","article-title":"Mogamulizumab-associated cutaneous granulomatous drug eruption mimicking mycosis fungoides but possibly indicating durable clinical response","volume":"155","author":"Chen","year":"2019","journal-title":"JAMA Dermatol"},{"key":"2023010800163646600_bjd20708-bib-0020","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2010.32.0630","article-title":"Clinical end points and response criteria in mycosis fungoides and S\u00e9zary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer","volume":"29","author":"Olsen","year":"2011","journal-title":"J Clin Oncol"},{"key":"2023010800163646600_bjd20708-bib-0021","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2007-03-055749","article-title":"Revisions to the staging and classification of mycosis fungoides and S\u00e9zary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)","volume":"110","author":"Olsen","year":"2007","journal-title":"Blood"},{"key":"2023010800163646600_bjd20708-bib-0022","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","article-title":"Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma","volume":"79","author":"Shimoyama","year":"1991","journal-title":"Br J Haematol"},{"key":"2023010800163646600_bjd20708-bib-0023","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano Classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"2023010800163646600_bjd20708-bib-0024","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/ijlh.12954","article-title":"Evaluation of next-generation sequencing-based clonality analysis of T-cell receptor gamma gene rearrangements based on a new interpretation algorithm","volume":"41","author":"Nollet","year":"2019","journal-title":"Int J Lab Hematol"},{"key":"2023010800163646600_bjd20708-bib-0025","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/ajcp\/aqy046","article-title":"The value of T-cell receptor gamma (TRG) clonality evaluation by next-generation sequencing in clinical hematolymphoid tissues","volume":"150","author":"Kansal","year":"2018","journal-title":"Am J Clin Pathol"},{"key":"2023010800163646600_bjd20708-bib-0026","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1111\/cas.13343","article-title":"Mogamulizumab for relapsed adult T-cell leukemia\u2013lymphoma: updated follow-up analysis of phase I and II studies","volume":"108","author":"Ishida","year":"2017","journal-title":"Cancer Sci"},{"key":"2023010800163646600_bjd20708-bib-0027","volume-title":"Levels of evidence: an introduction","author":"Centre for Evidence-Based Medicine"},{"key":"2023010800163646600_bjd20708-bib-0028","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE): version 5.0, 2017","author":"US Department of Health and Human Services"},{"key":"2023010800163646600_bjd20708-bib-0029","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2020-141041","article-title":"Characterization and outcomes in patients with mogamulizumab-associated skin reactions in the MAVORIC trial","volume":"136","author":"Musiek","year":"2020","journal-title":"Blood"},{"key":"2023010800163646600_bjd20708-bib-0030","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1111\/jdv.14797","article-title":"Mogamulizumab-induced photosensitivity in patients with mycosis fungoides and other T-cell neoplasms","volume":"32","author":"Masuda","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023010800163646600_bjd20708-bib-0031","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1158\/1078-0432.CCR-07-0610","article-title":"Immune function abnormalities in peripheral blood mononuclear cell cytokine expression differentiates stages of cutaneous T-cell lymphoma\/mycosis fungoides","volume":"14","author":"Chong","year":"2008","journal-title":"Cancer Clin Res"},{"key":"2023010800163646600_bjd20708-bib-0032","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1038\/leu.2008.224","article-title":"Malignant Tregs express low molecular splice forms of FOXP3 in S\u00e9zary syndrome","volume":"22","author":"Krejsgaard","year":"2008","journal-title":"Leukemia"},{"key":"2023010800163646600_bjd20708-bib-0033","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2340\/00015555-2257","article-title":"Emergence of photosensitivity with decreased Treg cells in a patient with mycosis fungoides treated with anti-CC chemokine receptor 4 antibody mogamulizumab","volume":"96","author":"Tatsuno","year":"2016","journal-title":"Acta Derm Venereol"},{"key":"2023010800163646600_bjd20708-bib-0034","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.jaad.2017.12.068","article-title":"Progression of undiagnosed cutaneous lymphoma after anti-tumor necrosis factor-alpha therapy","volume":"78","author":"Martinez-Escala","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2023010800163646600_bjd20708-bib-0035","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1067\/mjd.2002.120571","article-title":"Psoriasiform mycosis fungoides with fatal outcome after treatment with cyclosporine","volume":"47","author":"Zackheim","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"2023010800163646600_bjd20708-bib-0036","article-title":"Primary cutaneous CD30+ anaplastic large T cell lymphoma in a patient treated with cyclosporine for actinic reticuloid","volume":"2020","author":"Gambichler","year":"2020","journal-title":"Case Rep Dermatol Med"},{"key":"2023010800163646600_bjd20708-bib-0037","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/archdermatol.2009.119","article-title":"Fatal cytotoxic cutaneous lymphoma presenting as ulcerative psoriasis","volume":"145","author":"Weenig","year":"2009","journal-title":"Arch Dermatol"},{"key":"2023010800163646600_bjd20708-bib-0038","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1046\/j.1365-4362.2001.01256.x","article-title":"Transient CD30+ nodal transformation of cutaneous T-cell lymphoma associated with cyclosporine treatment","volume":"40","author":"Pielop","year":"2001","journal-title":"Int J Dermatol"},{"key":"2023010800163646600_bjd20708-bib-0039","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jdcr.2021.05.037","article-title":"Dupilumab as a therapy option for treatment refractory mogamulizumab-associated rash","volume":"14","author":"Trum","year":"2021","journal-title":"JAAD Case Rep"},{"key":"2023010800163646600_bjd20708-bib-0040","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jdcr.2020.12.010","article-title":"Acceleration of cutaneous T-cell lymphoma following dupilumab administration","volume":"8","author":"Russomanno","year":"2021","journal-title":"JAAD Case Rep"},{"key":"2023010800163646600_bjd20708-bib-0041","doi-asserted-by":"crossref","first-page":"131","DOI":"10.12788\/cutis.0066","article-title":"Cutaneous T-cell lymphoma and concomitant atopic dermatitis responding to dupilumab","volume":"106","author":"Mollanazar","year":"2020","journal-title":"Cutis"},{"key":"2023010800163646600_bjd20708-bib-0042","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/jdv.17001","article-title":"Rapid and sustained control of itch and reduction in Th2 bias by dupilumab in a patient with S\u00e9zary syndrome","volume":"35","author":"Steck","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023010800163646600_bjd20708-bib-0043","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jaad.2020.03.050","article-title":"Progression of cutaneous T-cell lymphoma after dupilumab: case review of 7 patients","volume":"83","author":"Espinosa","year":"2020","journal-title":"J Am Acad Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjd.20708","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjd.20708","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/186\/1\/153\/47428231\/bjd0153.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/186\/1\/153\/47428231\/bjd0153.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:06:27Z","timestamp":1676383587000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/186\/1\/153\/6593546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,1]]},"published-print":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.20708","relation":{},"ISSN":["1365-2133","0007-0963"],"issn-type":[{"value":"1365-2133","type":"electronic"},{"value":"0007-0963","type":"print"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2022,1,1]]},"assertion":[{"value":"2021-08-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}